<DOC>
	<DOC>NCT00551317</DOC>
	<brief_summary>This study is being conducted to provide initial safety, tolerability, PK and PD data that will allow further studies with darapladib in Japanese patients</brief_summary>
	<brief_title>A Study Investigating the Concentrations of Darapladib in Blood and the Safety of This Compound in Healthy Japanese Men</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Darapladib</mesh_term>
	<criteria>Inclusion criteria: Japanese males, 2064 years of age, inclusive Body weight &gt;50Kg Body Mass Index (BMI): 1828 Subjects must have lived outside of Japan no more than 10 years Nonsmoker or smokes fewer than 10 cigarettes/day Exclusion criteria: History of asthma, anaphylaxis or anaphylactoid reactions, severe allergic responses History of sensitivity to heparin or heparininduced thrombocytopenia History of alcohol/drug abuse or dependence within 12 months of the study Positive syphilis, HIV antibody, Hepatitis B, Hepatitis C History of cholecystectomy or biliary tract disease or history of liver disease Participation in a clinical study within 30 days prior to first dose Subject has been exposed to more than 4 chemical entities within 12 months Positive urine drug and alcohol at screening Subject has any medical history or clinically relevant abnormality that would make the subject ineligible for inclusion due to safety reasons.</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>SB480848,</keyword>
	<keyword>Japanese healthy volunteers</keyword>
	<keyword>darapladib,</keyword>
</DOC>